ライフサイエンスコーパス: mitogen

1 a implicate the neuroligin-3 ectodomain as a mitogen.

2 production in response to TB antigen and/or mitogen.

3 mation, extracellular matrix remodeling, and mitogens.

4 mbryonic zebrafish to identify cardiomyocyte mitogens.

5 mbers, and normal proliferative responses to mitogens.

6 screen identified multiple components of the mitogen activated protein kinase (MAPK) pathway enhancin

7 extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK) pathway.

8 nical nuclear factor kappa B (NF-kappaB) and mitogen activated protein kinase (MAPK) pathways have be

9 ncers contain genetic alterations within the Mitogen Activated Protein Kinase (MAPK) signaling networ

10 Mitogen activated protein kinase 4 (MPK4) is a multifunc

11 Further studies revealed that mitogen Activated Protein Kinase9 (CaMPK9) phosphorylate

12 biquitously expressed member of the atypical mitogen activated protein kinases (MAPKs) and the physio

13 -inflammatory pathways such as NF-kappaB and mitogen activated protein kinases (MAPKs), and the subse

14 MAP3K4 functions upstream of the p38 and JNK mitogen activated protein kinases (MAPKs).

15 an ancient and autoactivating member of the mitogen-activated kinase (MAPK) family and its regulatio

16 Disruption or knockdown of an Msb2-dependent mitogen-activated protein (MAP) kinase (HOG2) and an APS

17 ch engages the c-Jun N-terminal kinase (JNK) mitogen-activated protein (MAP) kinase and Fos and Jun t

18 t requires the c-Jun N-terminal kinase (JNK) mitogen-activated protein (MAP) kinase and the transcrip

19 magnetic resonance (NMR) measurements of the mitogen-activated protein (MAP) kinase ERK2 have shown t

20 Pharmacological inhibition of the mitogen-activated protein (MAP) kinase extracellular sig

21 e Using this approach, we identified the p38 mitogen-activated protein (MAP) kinase pathway and autop

22 ptosis, and its expression is facilitated by mitogen-activated protein (MAP) kinase-activated protein

23 ive responses characterized by activation of mitogen-activated protein (MAP) kinases and nuclear fact

24 ts in the UPR, such as activation of the JNK mitogen-activated protein (MAP) kinases or the pseudokin

25 KK1 can trigger various responses, including mitogen-activated protein (MAP) kinases, NF-kappaB signa

26 ion of extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK MAPK).

27 ia extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (ERK1/2 MAPK)-dependent

28 In this study, we identify a complete mitogen-activated protein kinase (MAPK or MPK) cascade,

29 mune signaling, including phosphorylation of mitogen-activated protein kinase (MAPK) 3 (MPK3) and MPK

30 MADD, the mitogen-activated protein kinase (MAPK) activating death

31 D family members 2, 3, and 4 (SMAD2/3/4) and mitogen-activated protein kinase (MAPK) activities, whic

32 was caused by an elevation in macrophage p38 mitogen-activated protein kinase (MAPK) activity.

33 through elevated and sustained activation of mitogen-activated protein kinase (MAPK) and AKT.

34 The expression of mitogen-activated protein kinase (MAPK) and endothelial

35 species (ROS) production, and activated p38 mitogen-activated protein kinase (MAPK) and p53.

36 Mutations at both interfaces interfered with mitogen-activated protein kinase (MAPK) and phosphoinosi

37 d proliferative (PRO) phenotypes linked with mitogen-activated protein kinase (MAPK) and signal trans

38 used it to analyze a set of D-motif peptide-mitogen-activated protein kinase (MAPK) associations to

39 Activation of the mitogen-activated protein kinase (MAPK) c-Jun N-terminal

40 idopsis, an extremely functionally redundant mitogen-activated protein kinase (MAPK) cascade is requi

41 reatment identified robust activation of p38 mitogen-activated protein kinase (MAPK) downstream of PK

42 daptors to regulate AT1R internalization and mitogen-activated protein kinase (MAPK) ERK1/2 activatio

43 increased levels of total and phosphorylated mitogen-activated protein kinase (MAPK) family members s

44 e a conserved feature of some members of the mitogen-activated protein kinase (MAPK) family.

45 Previous studies showed that activation of mitogen-activated protein kinase (MAPK) in diabetes prom

46 Smk1 is a meiosis-specific mitogen-activated protein kinase (MAPK) in Saccharomyces

47 Smk1 is a meiosis-specific mitogen-activated protein kinase (MAPK) in yeast that co

48 ype I priming, or the combination of Src and mitogen-activated protein kinase (MAPK) inhibitors, whic

49 Mitogen-activated protein kinase (MAPK) interacting kina

50 artially rescued by constitutively activated mitogen-activated protein kinase (MAPK) kinase kinase YO

51 Microbial pathogens often target the host mitogen-activated protein kinase (MAPK) network to suppr

52 paired the activity of key components of the mitogen-activated protein kinase (MAPK) pathway (p38 and

53 WASP-deficient lymphoma showed increased mitogen-activated protein kinase (MAPK) pathway activati

54 ling pathway, beta-arrestin recruitment, and mitogen-activated protein kinase (MAPK) pathway activati

55 brane (PM) correlates with activation of the mitogen-activated protein kinase (MAPK) pathway and subs

56 hodiesterase inhibitor and also modifies the mitogen-activated protein kinase (MAPK) pathway by downr

57 ptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controll

58 TGF-beta depends on RAS and mitogen-activated protein kinase (MAPK) pathway inputs f

59 The mitogen-activated protein kinase (MAPK) pathway is a key

60 Identifying additional mitogen-activated protein kinase (MAPK) pathway regulato

61 nsition (EMT), mediated, in part, by the p38 mitogen-activated protein kinase (MAPK) pathway respondi

62 that are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway(1,2).

63 BRAF, a kinase in the mitogen-activated protein kinase (MAPK) pathway, is muta

64 or (BDNF)-activated enzyme downstream of the mitogen-activated protein kinase (MAPK) pathway.

65 umor growth by constitutively activating the mitogen-activated protein kinase (MAPK) pathway.

66 ic alterations that converge to activate the mitogen-activated protein kinase (MAPK) pathway.

67 tivated kinase Ste20p, Cdc42p also regulates mitogen-activated protein kinase (MAPK) pathways (mating

68 Cellular signaling pathways, including the mitogen-activated protein kinase (MAPK) pathways, are re

69 dependent on the activation of the NF-kB and mitogen-activated protein kinase (MAPK) pathways, which

70 pattern recognition receptors activates the mitogen-activated protein kinase (MAPK) pathways, which

71 athways, whereas FGFR2b relied on downstream mitogen-activated protein kinase (MAPK) pathways.

72 nhancer of activated B cells (NF-kappaB) and mitogen-activated protein kinase (MAPK) pathways.

73 The mitogen-activated protein kinase (MAPK) phosphatases (MK

74 These express a mitogen-activated protein kinase (MAPK) programme that w

75 ll fusion, is mediated by Gbetagamma and the mitogen-activated protein kinase (MAPK) scaffold protein

76 In the absence of RASA1, dysregulated Ras mitogen-activated protein kinase (MAPK) signal transduct

77 PF included extracellular matrix remodeling, Mitogen-activated protein kinase (MAPK) signaling and AL

78 strains, we show that candidalysin activates mitogen-activated protein kinase (MAPK) signaling and ch

79 AS, and BRAF mutations which activate p44/42 mitogen-activated protein kinase (MAPK) signaling are fo

80 orted that kinase-dead BRAF variants amplify mitogen-activated protein kinase (MAPK) signaling by dim

81 to interact with both survival and apoptotic mitogen-activated protein kinase (MAPK) signaling cascad

82 ated calcium channel Cacophony (Cac) and the mitogen-activated protein kinase (MAPK) signaling cascad

83 ed by PTPN11, plays an essential role in RAS-mitogen-activated protein kinase (MAPK) signaling during

84 PD-L1 blockade with inhibition of oncogenic mitogen-activated protein kinase (MAPK) signaling may re

85 sor that is differentially regulated through mitogen-activated protein kinase (MAPK) signaling or gen

86 4b to act as a negative regulator of the RAS/mitogen-activated protein kinase (MAPK) signaling pathwa

87 S. cerevisiae plays crucial roles in various mitogen-activated protein kinase (MAPK) signaling pathwa

88 At the molecular level, besides the mitogen-activated protein kinase (MAPK) signaling pathwa

89 tein, VopA, has potent inhibitory effects on mitogen-activated protein kinase (MAPK) signaling pathwa

90 ally, inhibition of the PI3K, but not of the mitogen-activated protein kinase (MAPK) signaling pathwa

91 and activator of transcription 3 (STAT3) and mitogen-activated protein kinase (MAPK) signaling pathwa

92 kinase, p38, and c-Jun amino-terminal kinase mitogen-activated protein kinase (MAPK) signaling to eli

93 Elevated Pi activates mitogen-activated protein kinase (MAPK) signaling, encom

94 of RAF proto-oncogene, Ser/Thr kinase (Raf)-mitogen-activated protein kinase (MAPK) signaling, induc

95 c) Homology Phosphatase 2 (Shp2) to activate Mitogen-Activated Protein Kinase (MAPK) signaling, which

96 of Bmf expression, predominantly via p44/42 mitogen-activated protein kinase (MAPK) signaling.

97 cules, thus suppressing Raf-1 activation and mitogen-activated protein kinase (MAPK) signaling.

98 with genes implicated in focal adhesion and mitogen-activated protein kinase (MAPK) signaling.

99 1 (CK1) sites Cx43(S325A/328Y/330A), and the mitogen-activated protein kinase (MAPK) sites Cx43(S255/

100 gh autophosphorylation and activation of p38 mitogen-activated protein kinase (MAPK) via a non-canoni

101 identified NF-kappaB activator 1 (Act1), p38 mitogen-activated protein kinase (MAPK), Jun NH2-termina

102 ake of bacteria, which required PDK1, and of mitogen-activated protein kinase (MAPK)- and nuclear fac

103 kinase (IKK), c-jun N-terminal kinase (JNK), mitogen-activated protein kinase (MAPK)-extracellular re

104 of all pathogenic non-Dsg AuAbs involved p38 mitogen-activated protein kinase (MAPK)-mediated phospho

105 which transcription factors are released by mitogen-activated protein kinase (MAPK)-stimulated acety

106 lung injury is blunted by inhibitors of p38 mitogen-activated protein kinase (MAPK).

107 fungi that regulates the downstream HOG/p38 mitogen-activated protein kinase (MAPK).

108 Cystic kidneys showed increased mitogen-activated protein kinase (MAPK)/extracellular si

109 (PI3K)/Akt serine/threonine kinase (Akt) and mitogen-activated protein kinase (MAPK)/extracellular si

110 On the basis of our previous work on mitogen-activated protein kinase (MAPK)/extracellular si

111 an extremely potent allosteric inhibitor of mitogen-activated protein kinase (MAPK)/extracellular-si

112 f the JCI, Yokota et al. reveal that the p38 mitogen-activated protein kinase (MAPK)/IRE1alpha/XBP1 a

113 n of oncogenic Ras(V12) activates downstream mitogen-activated protein kinase (MEK-ERK) signaling to

114 Increases in the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK) and decrease

115 NASH development and the involvement of p38 mitogen-activated protein kinase (p38) activated by neut

116 CyTP genes is mediated by the conserved p38 mitogen-activated protein kinase (p38-MAPK) pathway.

117 Signal transduction pathways mediated by p38 mitogen-activated protein kinase (p38MAPK), extracellula

118 tly driven by genetic alterations in the RAS-mitogen-activated protein kinase (RAS/MAPK) pathway yet

119 hed in synaptic function and converge on Ras/mitogen-activated protein kinase (Ras/MAPK) signaling.

120 ovo missense variants in MAPK1, encoding the mitogen-activated protein kinase 1 (i.e., extracellular

121 l myenteric plexi and phosphorylation (p) of mitogen-activated protein kinase 1 (MAPK1) in the enteri

122 e P (SP), S100beta, GFAP, and phosphorylated mitogen-activated protein kinase 1 (pERK) were assessed

123 proteins, auxin stabilizes IAA33 protein via MITOGEN-ACTIVATED PROTEIN KINASE 14 (MPK14) and does not

124 e use Nicotiana attenuata plants silenced in mitogen-activated protein kinase 4 (irMPK4) - with low w

125 The strongest regulator of invasion was mitogen-activated protein kinase 4 (MAP4K4).

126 elated prognostic proteins, particularly the mitogen-activated protein kinase 6, probable protein pho

127 samples and xenograft mouse models revealed mitogen-activated protein kinase 7/matrix metallopeptida

128 beta-arrestin-dependent signaling responses, mitogen-activated protein kinase [i.e., extracellular si

129 nd extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase activation at the human

130 Mitogen-activated protein kinase activation by IL-8 has

131 Moreover, p38 mitogen-activated protein kinase activation emerges as a

132 for Ptpn6 in the negative regulation of p38 mitogen-activated protein kinase activation to control t

133 es G protein-coupled calcium ion signals and mitogen-activated protein kinase activity, and that its

134 ntracellular signaling pathways, such as the mitogen-activated protein kinase and AKT signaling casca

135 We targeted the mitogen-activated protein kinase and phosphatidylinosito

136 e ability of pharmacologic inhibition of the mitogen-activated protein kinase and PI3'K pathways to i

137 is revealed significant up-regulation of the mitogen-activated protein kinase and transforming growth

138 ulation in endothelial cells via JNK and p38 mitogen-activated protein kinase but not NF-kappaB.

139 identified OsPT8 as an interactor of a rice mitogen-activated protein kinase BWMK1, which is a regul

140 -X-C motif chemokine ligand 12 activates the mitogen-activated protein kinase extracellular-signal-re

141 preceded by decreased phosphorylation of p38 mitogen-activated protein kinase in HMuSC treated with C

142 eased proliferation and dysregulation of p38 mitogen-activated protein kinase in satellite cells comm

143 egulated protein kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinase in T lymphocytes.

144 ed by the accumulation of phosphorylated p38 mitogen-activated protein kinase in the nucleus, which d

145 Conversely, after dual MET/mitogen-activated protein kinase inhibition, tumor growt

146 vides a rationale for combining pan-ERBB and mitogen-activated protein kinase inhibitors as a therape

147 c target of rapamycin complex 1 (mTORC1) and mitogen-activated protein kinase interacting kinase (MNK

148 Finally, it reveals that mitogen-activated protein kinase interacting kinase-1 ha

149 tion of lipid A limits the activation of the mitogen-activated protein kinase Jun N-terminal protein

150 tor of transcription (STAT) (ruxolitinib) or mitogen-activated protein kinase kinase (MEK) (trametini

151 ines had IC(50) values less than 7 nM to the mitogen-activated protein kinase kinase (MEK) 1/2 inhibi

152 mutational status, and response to B-Raf and mitogen-activated protein kinase kinase (MEK) inhibition

153 We show that the mitogen-activated protein kinase kinase (MEK) inhibitor

154 As validation, distinct mitogen-activated protein kinase kinase (MEK) inhibitors

155 therapy with B-Raf proto-oncogene (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors

156 e/threonine-specific protein kinases (pRAF), mitogen-activated protein kinase kinase (pMEK), protein

157 A recently developed photoswitchable mitogen-activated protein kinase kinase 1 (MEK1) enzyme

158 Both VE-cadherin-silenced and mitogen-activated protein kinase kinase 1 (MEK1)-silence

159 ffector PI3K but instead require active MEK (mitogen-activated protein kinase kinase 1) signaling.

160 Hyperactivation of mitogen-activated protein kinase kinase 1/2 (MEK1/2), bu

161 ivated protein kinase kinase kinase 3)-MEK5 (mitogen-activated protein kinase kinase 5)-ERK5 (extrace

162 found REX1 to bind to the promoter region of mitogen-activated protein kinase kinase 6 (MKK6), thereb

163 ently described their potential in targeting mitogen-activated protein kinase kinase 7 (MKK7).

164 gamma) intraperitoneally for 3 d or with the mitogen-activated protein kinase kinase inhibitor selume

165 2 depletion in ECs elicited increased MEKK3 (mitogen-activated protein kinase kinase kinase 3)-MEK5 (

166 restingly, we observed that knockdown of the mitogen-activated protein kinase kinase kinase 4 (MAP3K4

167 Among the differentially expressed kinases, mitogen-activated protein kinase kinase kinase kinase 4

168 Mitogen-activated protein kinase kinase kinase kinase-4

169 Mitogen-Activated Protein Kinase Kinase Kinase Kinase-4

170 r their mechanisms of action using selective mitogen-activated protein kinase kinase MEK1/2, MEK5, an

171 s pyruvate dehydrogenase kinase 1, Akt, Raf, mitogen-activated protein kinase kinase, and ERK1/2.

172 tical residues within the catalytic loops of mitogen-activated protein kinase kinases (MAPKKs).

173 Although LF is known to cleave mitogen-activated protein kinase kinases (MEKs/MKKs) and

174 -in-class von Hippel-Lindau (VHL)-recruiting mitogen-activated protein kinase kinases 1 and 2 (MEK1/2

175 uce new KRAS(G12C) in response to suppressed mitogen-activated protein kinase output.

176 Furthermore, phosphorylation of the mitogen-activated protein kinase p38 was enhanced and ph

177 rticularly, we found that alterations of the mitogen-activated protein kinase pathway (KRAS and NRAS

178 Finally, we demonstrate mitogen-activated protein kinase pathway activation and

179 ward beta-arrestin recruitment and increased mitogen-activated protein kinase pathway activation.

180 llular signal-regulated protein kinase (ERK) mitogen-activated protein kinase pathway and that ERK in

181 ted, at least in part, via activation of the mitogen-activated protein kinase pathway following calci

182 M) in 60%, and phosphatidylinositol 3-kinase/mitogen-activated protein kinase pathway genes (eg, ERBB

183 phosphorylation of focal adhesion kinase and mitogen-activated protein kinase pathway leading to enha

184 th the extracellular signal-regulated kinase mitogen-activated protein kinase pathway that provides a

185 ectively, these findings demonstrate the ERK mitogen-activated protein kinase pathway to be integrall

186 ibed the paradoxical triggering of the human mitogen-activated protein kinase pathway when a small-mo

187 extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase pathway, consistent wit

188 ransducer and activator of transcription and mitogen-activated protein kinase pathways to regulate ce

189 y, pyrin domain-containing-3, and downstream mitogen-activated protein kinase pathways.

190 enotype was characterized by upregulation of mitogen-activated protein kinase pathways.

191 ofin (ARN), an antirheumatic drug, to induce mitogen-activated protein kinase phosphatase (MKP)-1 exp

192 bacterium tuberculosis (Mtb) by facilitating mitogen-activated protein kinase phosphatase 1 (MKP-1)-d

193 ed with a pharmacological agent that induces mitogen-activated protein kinase phosphatase have potent

194 past several years has elucidated a role for mitogen-activated protein kinase phosphatase to regulate

195 The Erk mitogen-activated protein kinase plays diverse roles in

196 2, PtrHAB13 and PtrHAB14 interacted with the mitogen-activated protein kinase protein PtrMPK7.

197 otein kinase C, cyclin-dependent kinase, and mitogen-activated protein kinase showed increased phosph

198 nger NHFs, PDAC cells exhibited increases in mitogen-activated protein kinase signaling and cellular

199 E-cadherin/epidermal growth factor receptor/mitogen-activated protein kinase signaling axis.

200 folded protein response, glycolysis, and the mitogen-activated protein kinase signaling cascade.

201 d causal link between LZTR1 dysfunction, RAS-mitogen-activated protein kinase signaling hyperactivity

202 terations in genes whose products are in the mitogen-activated protein kinase signaling pathway and a

203 g mechanism is a gain-of-function of the RAS-mitogen-activated protein kinase signaling pathway.

204 roteins in receptor tyrosine kinase, RAS, or mitogen-activated protein kinase signaling pathways.

205 se 4 (MAP3K4) gene, which contributes to p38 mitogen-activated protein kinase signaling, sensitized c

206 suppression of the inflammatory response and mitogen-activated protein kinase signaling.

207 extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase signaling.

208 cytoskeletal structures, and hyperactivated mitogen-activated protein kinase signaling.

209 ignalling, cell cycle regulatory signalling, mitogen-activated protein kinase signalling and pathways

210 apoptosis signal-regulating kinase 1 and p38 mitogen-activated protein kinase) activation.

211 of BRD4 is controlled, in part, by p38 MAPK (mitogen-activated protein kinase) and provide evidence o

212 K (RAS-extracellular signal-regulated kinase/mitogen-activated protein kinase) pathway integrates gro

213 ion of 101 gene transcripts, including MAPK (mitogen-activated protein kinase) signaling targets, HOP

214 s extracellular signal-regulated kinase 1/2, mitogen-activated protein kinase, and Src, shown by immu

215 Mitogen-activated protein kinase, kinase, kinase- 19 (MA

216 In contrast, mitogen-activated protein kinase, Src tyrosine kinase, a

217 eltaPMN) neutrophils displayed increased p38 mitogen-activated protein kinase-dependent Ripk1-indepen

218 al-related kinase 1/2 (pERK1/2), a marker of mitogen-activated protein kinase-ERK signal transduction

219 Targeting of the mitogen-activated protein kinase-interacting kinase (MNK

220 cellular senescence and is activated by p38 mitogen-activated protein kinase.

221 it also inhibited the phosphorylation of p38 mitogen-activated protein kinase.

222 ed that the rapidly accelerated fibrosarcoma/mitogen-activated protein kinase/extracellular signal-re

223 al stem-like (MSL) lineage downregulates the mitogen-activated protein kinase/extracellular signal-re

224 otein expression that was attenuated by MEK (mitogen-activated protein kinase/extracellular signal-re

225 al growth factor receptor (EGFR), as EGFR or mitogen-activated protein kinase/extracellular signal-re

226 Subsequently, activation of a mitogen-activated protein kinase/extracellular signal-re

227 ciated protein kinase 70 (ZAP-70), and three mitogen-activated protein kinases (extracellular signal-

228 cular chondrocytes via the inhibition of p38 mitogen-activated protein kinases (MAPK) and increasing

229 transcription factors are phosphorylated by mitogen-activated protein kinases (MAPK) in their transa

230 mapping revealed the involvement of K-RAS in mitogen-activated protein kinases (MAPK) pathway.

231 Mitogen-activated protein kinases (MAPK) such as p38 and

232 ar signal-regulated kinase 1 and 2 (ERK1/2), mitogen-activated protein kinases (MAPK), leading to unc

233 relatively rare member of the JNK family of mitogen-activated protein kinases (MAPK), phosphorylates

234 ral detail on docking interactions involving mitogen-activated protein kinases (MAPKs) and their subs

235 s diverse kinase pathways, which include the mitogen-activated protein kinases (MAPKs) ERK and p38, t

236 The catalytic activity of mitogen-activated protein kinases (MAPKs) is dynamically

237 t/MKP-1 pathway results in the inhibition of mitogen-activated protein kinases (MAPKs) JNK and p38.

238 Mitogen-activated protein kinases (MAPKs) mediate numero

239 we show that the rapid activation of clade-A mitogen-activated protein kinases (MAPKs) MPK3 and MPK6

240 Mitogen-activated protein kinases (MAPKs) regulate essen

241 Of note, two mitogen-activated protein kinases (MAPKs), extracellular

242 Two flg22-responsive mitogen-activated protein kinases (MAPKs), MPK3 and MPK6

243 (DUSP1), an endogenous negative regulator of mitogen-activated protein kinases (MAPKs), resulting in

244 some are under transcriptional regulation by mitogen-activated protein kinases (MAPKs).

245 nd ROS signals compromised the activation of mitogen-activated protein kinases (MPKs) 1/2 in leaves.

246 sion of sequestosome 1 (p62) and phospho-p38 mitogen-activated protein kinases (p-p38) showed a signi

247 were not affected in PAMP/DAMP activation of mitogen-activated protein kinases and expression of the

248 Activation of mitogen-activated protein kinases and NFkappaB signaling

249 p38 mitogen-activated protein kinases are key mediators of e

250 lular signal-regulated kinase), JNK, and p38 mitogen-activated protein kinases as well as NFkappaB (n

251 lear factor-kappaB, as well as activation of mitogen-activated protein kinases pathways.

252 ptation and stress tolerance, and in several mitogen-activated protein kinases signaling pathways inc

253 of reactive oxygen species and activation of mitogen-activated protein kinases upon exposure to flg22

254 ing a dual-specificity phosphatase targeting mitogen-activated protein kinases, as a type 2 diabetes

255 Mitogen-activated protein kinases, including c-Jun NH2-t

256 HAI1 or by HAI1-regulated kinases including mitogen-activated protein kinases, sucrose non-fermentin

257 ut increased cell invasion and activation of mitogen-activated protein kinases.

258 vers of healthy ducks and was upregulated in mitogen-activated splenic lymphocytes as well as in sple

259 genes whose products are involved in the RAS/mitogen-activating protein kinase (MAPK) pathway.

260 undant in blood and ascites fluid, is both a mitogen and chemoattractant for cancer cells.

261 In this model, competition between mitogen and DNA damage signalling over the course of the

262 oliferative response to glucose, a beta-cell mitogen and key regulator of beta-cell mass in response

263 ons of patients with idiopathic PAH and is a mitogen and migratory stimulus for pulmonary artery smoo

264 the hexosamine D-mannosamine (ManN) as an EC mitogen and survival factor for bovine and human microva

265 tection circuit linking responses to the Shh mitogen and the extracellular matrix to control cerebell

266 Mitogens and DNA damage have distinct sensing periods, g

267 e mice harboring an inactivating mutation of mitogen- and stress-activated protein kinase 1 (MSK1), a

268 cts of experience depend on an enzyme called mitogen- and stress-activated protein kinase 1 (MSK1).

269 Stimulation of the MAPK pathway results in mitogen- and stress-activated protein kinase 1/2 (MSK1/2

270 diminished as shown by reduced responses to mitogens as well as diminished cytokine secretion.

271 the RAF-MEK-ERK pathway, the first described mitogen-associated protein kinase (MAPK) cascade, mediat

272 Cells escape the need for mitogens at a restriction point several hours before ent

273 trary to the textbook model that cells sense mitogen availability only in the G(1) cell cycle phase,

274 ork of a minimal theoretical model based on "mitogen competition." We propose that this model provide

275 The level of ubiquitinated ELK-1 rises in mitogen-deprived cells and falls upon mitogen stimulatio

276 that PDAC cells rely on a stromal supply of mitogens for their proliferative needs.

277 the integrator that proportionally converts mitogen history into corresponding levels of cyclin D in

278 But whether exogenous T3 functions as a mitogen in post-P6 murine hearts is not known.

279 is overexpressed in > 60% of TNBCs, drives a mitogen-independent G1/S cell cycle transition through c

280 S phase entry is mitogen-independent in the daughter G1 phase, but remain

281 d hepatocytes responded similarly to hepatic mitogens, indicating that proliferation kinetics are unr

282 creased immune responsiveness with decreased mitogen-induced upregulation of IFN-gamma, TNF, IL-6, CX

283 rexpression potently increased the levels of mitogen-inducible gene 6 (MIG6), which inhibits EGFR and

284 through C-terminal cross-linking of the tear mitogen lacritin, leading to significant loss of lacriti

285 ive of a change resulting from exposure to a mitogen, ligand, or antigen for which it is specific, as

286 cal enterotoxin B and Mycoplasma arthritidis mitogen, on influenza virus- and/or cytomegalovirus-spec

287 mage response pathways, and is distinct from mitogen removal and spontaneous quiescence.

288 Mitogen removal in G1 results in a gradual loss of CDK4/

289 ent hysteresis, in CDK4/6 activity following mitogen removal that sustains Rb hyperphosphorylation, d

290 The mitogen-responsive, ETS-domain transcription factor ELK-

291 We identified the nuclear kinase mitogen-sensitive kinase 1 (MSK1) as a downstream target

292 r cell cycle and that even a 1-hour lapse in mitogen signaling can influence cell proliferation more

293 his study uncovers a mechanism whereby serum mitogen signaling regulates Rabin8 preciliary traffickin

294 t baseline and following mycobacterial Ag or mitogen stimulation in individuals with LTB with (Strong

295 ses in mitogen-deprived cells and falls upon mitogen stimulation or oncogene expression.

296 No differences were observed upon mitogen stimulation.

297 nts' blood by serial dilution and repetitive mitogen stimulation.

298 15/19 functions as a profibrotic mediator or mitogen to HSCs and increased BAs in Fgf15(-/-) mice lea

299 not act as a direct profibrotic mediator or mitogen to HSCs in our models, and the protection agains

300 Multicellular organisms use mitogens to regulate cell proliferation, but how fluctua